01—Abstract
Summary
Summary of the 8-K filed January 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) disclosed in this Form 8-K, filed January 29, 2026, that on January 28, 2026 it entered into a Second Amendment to its Receivables Purchase Agreement with Labcorp Receivables LLC, Laboratory Corporation of America Holdings, PNC Bank, National Association (as administrative agent), and the other parties thereto.
The company acknowledged and agreed to the amendment. Under the RPA Amendment, the scheduled termination date was extended to January 26, 2029. A committed $125 milliona accordion facility was added, allowing Labcorp Receivables, at its option, to increase the facility limit from $700 million to up to $825 million at any time on or before May 29, 2026.
The 0.10%b SOFR adjustment previously added to capital accruing yield at daily 1M SOFR or term SOFR rate was removed. The filing also states that Labcorp Receivables is a separate legal entity with its own creditors, who will have access to its assets before those assets become available to the Company.
Labcorp Receivables assets are therefore not available to pay creditors of the Company or its subsidiaries (other than Labcorp Receivables), although collections in excess of amounts needed to repay the Purchasers and other Labcorp Receivables creditors may be remitted to the Company. The full amendment is filed as Exhibit 10.1.
02—Key points
Key Highlights
- Receivables Purchase Agreement amended on January 28, 2026 via the Second Amendment, involving Labcorp Receivables LLC, Laboratory Corporation of America Holdings, and PNC Bank, National Association as administrative agent
- Scheduled termination date extended to January 26, 2029
- Committed $125 million accordion facility added, allowing the facility limit to rise from $700 million to up to $825 million on or before May 29, 2026, at Labcorp Receivables' option
- 0.10% SOFR adjustment previously added to the capital accruing yield was removed
- Labcorp Receivables is a bankruptcy-remote separate legal entity; its assets are not available to pay Company or subsidiary creditors, though excess collections may be remitted to the Company
- Filed under Item 1.01 (Material Definitive Agreement) and Item 2.03 (Direct Financial Obligation), with the full amendment as Exhibit 10.1
03—Questions
Frequently Asked Questions
What did Labcorp change in its receivables facility?
The Second Amendment to the Receivables Purchase Agreement extended the scheduled termination date to January 26, 2029, added a committed $125 million accordion, and removed the 0.10% SOFR adjustment from the capital accruing yield.
How large can the receivables facility become?
The facility limit is $700 million. Labcorp Receivables may, at its option, increase it to up to $825 million at any time on or before May 29, 2026, under the committed $125 million accordion.
Who are the parties to the amendment?
The amendment is among Labcorp Receivables LLC, Laboratory Corporation of America Holdings, PNC Bank, National Association as administrative agent, and the other parties named in the agreement. The Company acknowledged and agreed to it.
Are Labcorp Receivables assets available to Labcorp's general creditors?
No. Labcorp Receivables is a separate legal entity with its own creditors, who have access to its assets first. Its assets are not available to pay creditors of the Company or its subsidiaries, though collections exceeding amounts owed to the Purchasers and other Labcorp Receivables creditors may be remitted to the Company.
04—Continue